Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Comprehensive epigenetic landscape of rheumatoid arthritis fibroblast-like synoviocytes.

Ai R, Laragione T, Hammaker D, Boyle DL, Wildberg A, Maeshima K, Palescandolo E, Krishna V, Pocalyko D, Whitaker JW, Bai Y, Nagpal S, Bachman KE, Ainsworth RI, Wang M, Ding B, Gulko PS, Wang W, Firestein GS.

Nat Commun. 2018 May 15;9(1):1921. doi: 10.1038/s41467-018-04310-9.

2.

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.

Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R, Russell P, Kennedy C, Fereday S, Hung J, Galletta L, Hogg R, Wain GV, Brand A, Balleine R, MacConaill L, Palescandolo E, Hunter SM, Campbell I, Dobrovic A, Wong SQ, Do H, Clarke CL, Harnett PR, Bowtell DD, deFazio A; Australian Ovarian Cancer Study (AOCS).

Clin Cancer Res. 2014 Dec 15;20(24):6618-30. doi: 10.1158/1078-0432.CCR-14-1292. Epub 2014 Oct 14. Erratum in: Clin Cancer Res. 2016 Aug 15;22(16):4272.

3.

Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

MacConaill LE, Garcia E, Shivdasani P, Ducar M, Adusumilli R, Breneiser M, Byrne M, Chung L, Conneely J, Crosby L, Garraway LA, Gong X, Hahn WC, Hatton C, Kantoff PW, Kluk M, Kuo F, Jia Y, Joshi R, Longtine J, Manning A, Palescandolo E, Sharaf N, Sholl L, van Hummelen P, Wade J, Wollinson BM, Zepf D, Rollins BJ, Lindeman NI.

J Mol Diagn. 2014 Nov;16(6):660-72. doi: 10.1016/j.jmoldx.2014.06.004. Epub 2014 Aug 23.

4.

Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment.

Sadow PM, Priolo C, Nanni S, Karreth FA, Duquette M, Martinelli R, Husain A, Clohessy J, Kutzner H, Mentzel T, Carman CV, Farsetti A, Henske EP, Palescandolo E, Macconaill LE, Chung S, Fadda G, Lombardi CP, De Angelis AM, Durante O, Parker JA, Pontecorvi A, Dvorak HF, Fletcher C, Pandolfi PP, Lawler J, Nucera C.

J Natl Cancer Inst. 2014 Jul 25;106(8). pii: dju182. doi: 10.1093/jnci/dju182. Print 2014 Aug.

5.

Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency.

Hanna MC, Go C, Roden C, Jones RT, Pochanard P, Javed AY, Javed A, Mondal C, Palescandolo E, Van Hummelen P, Hatton C, Bass AJ, Chun SM, Na DC, Kim TI, Jang SJ, Osarogiagbon RU, Hahn WC, Meyerson M, Garraway LA, MacConaill LE.

PLoS One. 2013 Sep 16;8(9):e74950. doi: 10.1371/journal.pone.0074950. eCollection 2013.

6.

Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.

Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT, Quick CM, Laury A, Katz IT, Hahn WC, Matulonis UA, Hirsch MS.

Cancer. 2013 Nov 1;119(21):3776-83. doi: 10.1002/cncr.28288. Epub 2013 Aug 23.

7.

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.

Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, Dunn IF, Beroukhim R.

Nat Genet. 2013 Mar;45(3):285-9. doi: 10.1038/ng.2526. Epub 2013 Jan 20.

8.

High throughput mass spectrometry-based mutation profiling of primary uveal melanoma.

Daniels AB, Lee JE, MacConaill LE, Palescandolo E, Van Hummelen P, Adams SM, DeAngelis MM, Hahn WC, Gragoudas ES, Harbour JW, Garraway LA, Kim IK.

Invest Ophthalmol Vis Sci. 2012 Oct 9;53(11):6991-6. doi: 10.1167/iovs.12-10427.

9.

High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations.

Maeng CH, Lee J, van Hummelen P, Park SH, Palescandolo E, Jang J, Park HY, Kang SY, MacConaill L, Kim KM, Shim YM.

PLoS One. 2012;7(8):e41655. doi: 10.1371/journal.pone.0041655. Epub 2012 Aug 3.

10.

BRAF mutations in metanephric adenoma of the kidney.

Choueiri TK, Cheville J, Palescandolo E, Fay AP, Kantoff PW, Atkins MB, McKenney JK, Brown V, Lampron ME, Zhou M, Hirsch MS, Signoretti S.

Eur Urol. 2012 Nov;62(5):917-22. doi: 10.1016/j.eururo.2012.05.051. Epub 2012 Jun 9.

11.

High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma.

Lee J, van Hummelen P, Go C, Palescandolo E, Jang J, Park HY, Kang SY, Park JO, Kang WK, MacConaill L, Kim KM.

PLoS One. 2012;7(6):e38892. doi: 10.1371/journal.pone.0038892. Epub 2012 Jun 18.

12.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA.

Nature. 2012 Mar 28;483(7391):603-7. doi: 10.1038/nature11003. Erratum in: Nature. 2012 Dec 13;492(7428):290.

13.

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.

Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, MacConaill LE, Robert C, Hofbauer GF, McArthur GA, Schadendorf D, Garraway LA.

J Clin Oncol. 2012 Jan 20;30(3):316-21. doi: 10.1200/JCO.2011.36.7680. Epub 2011 Nov 7.

14.

High throughput interrogation of somatic mutations in high grade serous cancer of the ovary.

Matulonis UA, Hirsch M, Palescandolo E, Kim E, Liu J, van Hummelen P, MacConaill L, Drapkin R, Hahn WC.

PLoS One. 2011;6(9):e24433. doi: 10.1371/journal.pone.0024433. Epub 2011 Sep 8.

15.

Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.

Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M.

J Natl Cancer Inst. 2009 Apr 1;101(7):519-32. doi: 10.1093/jnci/djp030. Epub 2009 Mar 24.

16.

Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer.

Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler ME, Mucci L, Giovannucci E, Finn S, Loda M.

Lab Invest. 2008 Dec;88(12):1340-8. doi: 10.1038/labinvest.2008.97. Epub 2008 Oct 6.

17.

deltaN-p73 is a transcriptional target of the PML/RARalpha oncogene in myeloid differentiation.

Mainardi S, Pelosi A, Palescandolo E, Riccioni R, Fontemaggi G, Diverio D, Testa U, Sacchi A, Grignani F, Lo-Coco F, Levrero M, Blandino G, Rizzo MG.

Cell Death Differ. 2007 Nov;14(11):1968-71. Epub 2007 Aug 10. No abstract available.

18.

Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma.

Esposito V, Palescandolo E, Spugnini EP, Montesarchio V, De Luca A, Cardillo I, Cortese G, Baldi A, Chirianni A.

Clin Cancer Res. 2006 Apr 15;12(8):2634-9.

19.

Pkn is a novel partner of cyclin T2a in muscle differentiation.

Cottone G, Baldi A, Palescandolo E, Manente L, Penta R, Paggi MG, De Luca A.

J Cell Physiol. 2006 Apr;207(1):232-7.

PMID:
16331689
20.

Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells.

Alisi A, Mele R, Spaziani A, Tavolaro S, Palescandolo E, Balsano C.

J Cell Physiol. 2005 Oct;205(1):25-31.

PMID:
15880455
21.

Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress.

Baldi A, Lombardi D, Russo P, Palescandolo E, De Luca A, Santini D, Baldi F, Rossiello L, Dell'Anna ML, Mastrofrancesco A, Maresca V, Flori E, Natali PG, Picardo M, Paggi MG.

Clin Cancer Res. 2005 May 1;11(9):3175-83.

22.

DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest.

Vossio S, Palescandolo E, Pediconi N, Moretti F, Balsano C, Levrero M, Costanzo A.

Oncogene. 2002 May 23;21(23):3796-803.

23.

Supplemental Content

Loading ...
Support Center